Guggenheim Initiates Coverage On ADC Therapeutics with Buy Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Michael Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Buy rating and a price target of $11.

March 28, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Michael Schmidt initiates coverage on ADC Therapeutics with a Buy rating and a price target of $11.
The initiation of coverage by Guggenheim with a Buy rating and a price target of $11 suggests a positive outlook on ADC Therapeutics' stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100